Trust Signals
Authored by the FormBlends Medical Team. Last reviewed 2026-05-29. Evidence graded using GRADE-style confidence levels. All cited trials are real and named. No affiliate language or promotional framing. Regulatory facts sourced from FDA.gov and published clinical literature.Key Takeaways
- Sermorelin is a 29-amino-acid GHRH analog with a documented FDA approval history (Geref); ipamorelin is a synthetic pentapeptide GHSR-1a agonist that has never been FDA-approved and as of 2024 cannot be legally compounded in the US under 503A or 503B.
- The two peptides act on entirely different receptors, making combination use mechanistically rational, but human RCT evidence for the specific combination is absent.
- Ipamorelin's selectivity advantage over older GHRPs (less cortisol stimulation) is supported by preclinical and small human data, not large RCTs.
- Sermorelin's body composition benefits in adults with normal GH secretion have not been demonstrated in adequately powered trials; existing positive data come from GH-deficient populations.
- Both peptides degrade rapidly in solution; reconstituted preparations should be used within the compounding pharmacy's specified window, typically 30 days refrigerated, and degraded product shows no visible warning signs.
Ipamorelin Peptide vs Sermorelin: Direct Answer
Ipamorelin and sermorelin both raise GH levels but through completely different receptors and with very different regulatory and evidence profiles. Sermorelin has more human clinical data and a prior FDA approval. Ipamorelin is more restricted, with stronger selectivity data but weaker body-composition evidence. Neither is FDA-approved for adult longevity or body composition use.Table of Contents
- How do ipamorelin and sermorelin actually work?
- Evidence ledger: what does the research actually support?
- Head-to-head comparison table
- What doses are used in human studies?
- Is ipamorelin really more selective than sermorelin?
- What most comparison pages get wrong
- Stability and formulation: the part no one explains
- Regulatory status in 2024 and beyond
- How to read a COA and evaluate a peptide product
- Frequently asked questions
- Sources
How Do Ipamorelin and Sermorelin Actually Work?
Sermorelin is a synthetic analog of the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH 1-29). It binds the GHRH receptor (GHRH-R), a Gs-coupled GPCR expressed on anterior pituitary somatotrophs. Receptor activation raises intracellular cAMP, which triggers calcium influx and GH exocytosis. The native GHRH molecule is 44 amino acids; the 1-29 fragment retains full receptor binding and bioactivity. Sermorelin's plasma half-life is roughly 10 to 12 minutes in humans, consistent with rapid N-terminal cleavage by dipeptidyl peptidase IV (DPP-IV).
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the growth hormone secretagogue receptor type 1a (GHSR-1a), the same receptor activated by the endogenous hormone ghrelin. GHSR-1a is a Gq-coupled GPCR; its activation stimulates phospholipase C, raises intracellular IP3 and calcium, and triggers GH release through a pathway distinct from and additive to GHRH-R signaling. The two pathways converge on somatotroph calcium signaling but engage different second-messenger cascades, which is why the combination can produce more GH than either agent alone.
Ipamorelin was designed at Novo Nordisk from the earlier GHRP scaffold, specifically to reduce the off-target ACTH, cortisol, and prolactin stimulation seen with GHRP-2 and GHRP-6. Its half-life in preclinical models is roughly 2 hours, longer than sermorelin, because the D-amino acids and C-terminal amide block proteolytic degradation.
What this mechanism does NOT prove: That either peptide produces clinically meaningful body composition changes in adults with intact GH axes. The GH pulse is real; translating that pulse into lean mass gain or fat loss requires sustained IGF-1 elevation and tissue-level responsiveness that has not been robustly demonstrated in healthy adults for either compound.
Evidence Ledger: What Does the Research Actually Support?
| Claim | Best Evidence Type | Best Available Source | Effect Direction | Confidence |
|---|---|---|---|---|
| Sermorelin raises GH and IGF-1 in GH-deficient adults | Multiple RCTs and controlled trials | Thorner et al. and FDA NDA review data (Geref) | Positive, dose-dependent | High |
| Sermorelin improves body composition in GH-deficient adults | Controlled clinical trials, GH-deficient populations | Published sermorelin trials in pediatric and adult GHD | Positive in deficient subjects | Moderate |
| Sermorelin improves body composition in GH-sufficient adults | No adequately powered RCT identified | Absent | Unknown | Very Low |
| Ipamorelin raises GH in humans | Small human pharmacodynamic studies | Raun et al. 1998 (Eur J Endocrinol); Helsinn ClinicalTrials.gov filings | Positive | Moderate |
| Ipamorelin causes less cortisol/ACTH stimulation than GHRP-6 | Animal studies + one small human comparison | Raun et al. 1998 | Favorable (less off-target) | Moderate (animal-dominant) |
| Ipamorelin improves body composition in humans | No published RCT for this endpoint | Absent | Unknown | Very Low |
| GHRH + GHSR agonist combination is synergistic for GH release | Preclinical studies, mechanistic human PD data | Bowers et al.; multiple animal studies | Positive, additive to synergistic | Moderate |
| Either peptide is safe for long-term use in adults | No long-term safety RCT for either agent in this population | Absent | Unknown | Very Low |
Head-to-Head Comparison Table
| Feature | Sermorelin | Ipamorelin |
|---|---|---|
| Structure | 29-amino-acid peptide (GHRH analog) | Pentapeptide (5 amino acids, synthetic) |
| Receptor target | GHRH-R (Gs-coupled) | GHSR-1a (Gq-coupled, ghrelin receptor) |
| Plasma half-life (human) | Roughly 10 to 12 minutes | Estimated 2 hours (preclinical; limited human data) |
| FDA approval history | Yes (Geref, voluntarily withdrawn ~2008) | No |
| US compounding status (2024) | Compoundable (with caveats) | Prohibited under 503A/503B as of 2024 FDA rule |
| Human RCT data for body composition | In GHD populations only | None identified |
| Cortisol/ACTH stimulation | Minimal at therapeutic doses | Less than GHRP-6; precise human magnitude unclear |
| Combination potential | Can be combined with GHSR agonists | Can be combined with GHRH analogs |
| Cost (compounded, approximate) | Generally lower due to longer history | Generally higher; supply restricted post-2024 |
| Compared to recombinant hGH | Less potent GH elevation; preserves pulsatility; no black-box equivalent | Less studied; no comparison RCT vs. hGH |
Where the peptides lose vs. recombinant hGH: For diagnosed GH deficiency, FDA-approved recombinant hGH has far more evidence for body composition, bone density, and quality-of-life outcomes than either secretagogue. The secretagogue advantage is preserving the natural pulsatile pattern and avoiding exogenous GH's suppressive feedback, but this theoretical advantage has not translated into a demonstrated clinical superiority in head-to-head trials.
What Doses Are Used in Human Studies?
Sermorelin clinical trial data, including the FDA NDA package, used weight-based or fixed subcutaneous dosing. Adult protocols in published literature typically reference 0.2 to 0.3 mg administered subcutaneously at bedtime to coincide with endogenous GH pulsatility. The bedtime timing is physiologically justified because endogenous GH surges occur during slow-wave sleep, and sermorelin amplifies this existing pulse rather than creating a pharmacologically forced one.
Ipamorelin human pharmacodynamic studies by Raun et al. (1998, European Journal of Endocrinology) used intravenous doses in a range from roughly 1 to 10 mcg/kg in healthy subjects. Subcutaneous dosing in subsequent research contexts has ranged from 200 to 600 mcg per injection. The Helsinn clinical program investigating ipamorelin for postoperative ileus (ClinicalTrials.gov identifiers available) used IV administration, which is not directly comparable to subcutaneous research protocols.
No dosing regimen for either peptide is FDA-approved for adult anti-aging, body composition, or performance purposes. The figures above are research-context reference points only.
Is Ipamorelin Really More Selective Than Sermorelin?
The "selectivity" claim for ipamorelin refers specifically to reduced stimulation of cortisol, ACTH, and prolactin compared to earlier GHRP compounds. Raun et al. (1998) demonstrated in swine and in a small human cohort that ipamorelin produced robust GH release without the cortisol and ACTH co-stimulation seen with GHRP-6 at equimolar doses. This is a meaningful distinction from GHRP-6, not necessarily from sermorelin.
Sermorelin, acting on GHRH-R, is itself physiologically targeted to somatotrophs. At therapeutic doses, it does not meaningfully stimulate cortisol or prolactin because GHRH-R expression on adrenocortical or lactotroph cells is minimal. So the practical selectivity gap between ipamorelin and sermorelin is narrower than most comparison articles imply. Both are reasonably selective relative to GHRP-6; ipamorelin's advantage is primarily over the older GHRP class, not over sermorelin specifically.
What Most Comparison Pages Get Wrong
1. Conflating the mechanism with the outcome. Many pages state that because ipamorelin raises GH, it builds muscle or burns fat. GH elevation is a surrogate endpoint. The clinical endpoints (lean mass, fat mass, performance, longevity markers) require their own evidence, and for ipamorelin in healthy adults, that evidence does not exist at RCT level.
2. Treating compounded ipamorelin as freely available. As of 2024, the FDA finalized action placing ipamorelin on the list of bulk drug substances that cannot be used in compounding under Section 503A (traditional pharmacies) or 503B (outsourcing facilities). This was not a theoretical future restriction; it materially affected the US compounded peptide market. Any page describing ipamorelin as "widely available through compounding pharmacies" without this caveat is out of date or misleading.
3. Presenting the combination as proven. The GHRH-plus-GHSR-agonist combination is scientifically rational and preclinically supported. It is not proven in human RCTs at the body-composition level. Mechanistic synergy and clinical efficacy are different things.
4. Ignoring the GH-sufficient adult problem. Sermorelin's evidence base is almost entirely in GH-deficient populations (pediatric short stature, adult-onset GHD). GH-sufficient adults have intact feedback mechanisms. Sermorelin in this population will amplify existing pulses, but the degree of additional IGF-1 and body composition effect is not established.
Stability and Formulation: The Part No One Explains
Both sermorelin and ipamorelin are supplied as lyophilized (freeze-dried) powders. Lyophilization removes water, which is the primary driver of peptide hydrolysis and oxidation. In the dry state, refrigerated at 2 to 8 degrees C and protected from light, both peptides are relatively stable for months.
Why reconstitution matters so much: Once dissolved, peptide bonds become vulnerable to hydrolysis, a reaction accelerated by heat, pH extremes, and light. The rate follows Arrhenius kinetics: every 10 degree C rise roughly doubles the degradation rate. A reconstituted vial left at room temperature degrades meaningfully faster than one kept refrigerated. Most compounding pharmacies specify a 30-day beyond-use date for reconstituted preparations stored at 2 to 8 degrees C, based on general peptide stability data rather than compound-specific kinetic studies for these exact molecules.
The critical gotcha: Degraded peptide in solution is visually indistinguishable from intact peptide. There is no color change, no cloudiness (absent contamination), no odor. You cannot tell by looking whether a reconstituted vial stored at inconsistent temperatures contains active peptide or hydrolysis fragments. This is fundamentally different from, say, a small molecule drug where stability is routinely tested per USP monograph.
Bacteriostatic vs. sterile water: Bacteriostatic water (0.9% benzyl alcohol) is standard for multi-dose reconstitution because it suppresses microbial growth over the use period. Sterile water for injection is single-use; using it for a multi-dose vial increases contamination risk. The benzyl alcohol in bacteriostatic water at typical concentrations (9 mg/mL) is well tolerated subcutaneously at the volumes used in peptide dosing.
Regulatory Status in 2024 and Beyond
Sermorelin acetate (brand name Geref) received FDA approval for treatment of idiopathic growth hormone deficiency in children and as a diagnostic tool. Serono voluntarily withdrew the product from the US market around 2008, citing commercial rather than safety reasons. Sermorelin remains on the FDA's list of bulk drug substances that can be used in compounding (Category 1 under 503A), meaning licensed compounding pharmacies can prepare it lawfully for patients with a valid prescription.
Ipamorelin's trajectory is sharply different. It was never approved. Helsinn Healthcare conducted clinical development for postoperative GI motility (ipamorelin was investigated as a GI prokinetic given its partial GI tract action through peripheral GHSR-1a), but no NDA was filed. In 2024, the FDA published its final rule identifying ipamorelin as a bulk drug substance that does not meet compounding criteria, citing insufficient clinical evidence of safety and efficacy. This restricts US practitioner access significantly, and any US-based clinic offering compounded ipamorelin after this ruling is operating outside the FDA's compounding framework.
How to Read a COA and Evaluate a Peptide Product
A Certificate of Analysis (COA) from a compounding pharmacy or research supplier should include, at minimum: identity confirmation (typically HPLC or mass spectrometry), purity percentage (greater than 98% is standard for research-grade peptides), endotoxin testing (LAL assay, critical for injectable preparations), sterility testing, and the specific lot number and test date.
Red flags on a COA:
- Purity stated without specifying the method (HPLC vs. UV vs. TLC give different numbers).
- No endotoxin result. Endotoxin contamination is the primary safety concern in injectable peptides and cannot be detected by purity testing alone.
- Test date significantly predating the product's sale. Stability is time-dependent.
- Third-party lab not named or not independently verifiable.
Reconstitution math for sermorelin (example, not a dosing recommendation): If a vial contains 2 mg of lyophilized sermorelin and you add 2 mL of bacteriostatic water, the concentration is 1 mg/mL (1000 mcg/mL). A 0.2 mg dose would require drawing 0.2 mL (20 units on a 100-unit insulin syringe). Always confirm the vial label concentration with the dispensing pharmacy and recalculate independently.
What degraded product looks like: As noted above, nothing visible. This is why proper cold-chain handling from pharmacy to patient is not optional. If a vial has been shipped without cold packaging in warm weather, treat the product as compromised regardless of appearance.
Frequently Asked Questions
What is the main difference between ipamorelin and sermorelin?
Sermorelin is a truncated analog of endogenous GHRH (29 amino acids) that binds the GHRH receptor. Ipamorelin is a synthetic pentapeptide GHSR agonist (ghrelin receptor) with no structural relation to GHRH. They stimulate GH release through entirely different receptor pathways and can be combined for additive effect.
Which peptide raises GH levels more, ipamorelin or sermorelin?
Head-to-head human data are absent. In animal studies, combining a GHRH analog with a ghrelin receptor agonist produces synergistic GH release well above either agent alone. For sermorelin specifically, FDA-era clinical data showed meaningful GH pulse augmentation in GH-deficient adults. Ipamorelin human pharmacodynamic data are limited to small studies.
Is sermorelin FDA-approved?
Sermorelin acetate (Geref) was FDA-approved for pediatric GH deficiency diagnosis and treatment. The branded product was voluntarily withdrawn from the US market around 2008. It remains available as a compounded preparation, which is not FDA-approved as a finished drug product.
Is ipamorelin FDA-approved?
No. Ipamorelin has not received FDA approval for any indication. In 2024, the FDA placed ipamorelin on its list of bulk drug substances that may not be used in compounding, significantly restricting its US availability.
What doses are used in human studies for each peptide?
Sermorelin is commonly referenced at 0.2 to 0.3 mg subcutaneously at bedtime in adult clinical protocols. Ipamorelin doses in human studies have ranged from 200 to 600 mcg per injection subcutaneously. No dosing has FDA approval for adult longevity or body composition use.
Can ipamorelin and sermorelin be used together?
The combination is mechanistically rational because they act on different receptors (GHRH-R and GHSR-1a). Preclinical data support synergistic GH release when GHRH analogs and ghrelin mimetics are co-administered. Human RCT evidence for the specific ipamorelin plus sermorelin combination is absent.
What are the side effects of ipamorelin vs sermorelin?
Sermorelin's clinical trial adverse event profile includes injection-site redness, flushing, headache, and dizziness. Ipamorelin is reported in smaller studies to cause fewer cortisol and prolactin side effects compared to older GHRP secretagogues like GHRP-6. Both carry theoretical risks of GH-driven IGF-1 elevation.
How should ipamorelin and sermorelin be stored?
Both lyophilized peptides should be stored refrigerated (2 to 8 degrees C) before reconstitution and protected from light. After reconstitution with bacteriostatic water, most compounding pharmacy guidelines recommend use within 30 days under refrigeration. Peptide bonds are susceptible to hydrolysis; elevated temperature accelerates degradation.
Why did the FDA restrict compounded ipamorelin?
In 2024, the FDA finalized a rule identifying ipamorelin as a drug substance that cannot be used in compounding under 503A or 503B because it does not meet the criteria for inclusion on the bulk drug substances list. The primary concern was insufficient clinical data to support compounded use outside of an IND.
Does sermorelin increase IGF-1 meaningfully in adults?
In clinical trials of sermorelin in GH-deficient adults, IGF-1 levels increased significantly with nightly subcutaneous dosing over weeks to months. Individuals with normal GH secretion show blunted responses due to intact feedback. IGF-1 normalization was a primary endpoint in several sermorelin trials.
Which peptide is more selective for GH release?
Ipamorelin produces less cortisol and ACTH stimulation than older GHRPs like GHRP-6 in preclinical and small clinical studies. Sermorelin, acting on GHRH-R expressed primarily on somatotrophs, is also physiologically selective and does not significantly stimulate cortisol or prolactin at therapeutic doses. The practical selectivity gap between the two is narrow.
How long does it take to see effects from sermorelin or ipamorelin?
In sermorelin trials for GH deficiency, measurable IGF-1 increases were typically seen within 4 to 8 weeks of nightly dosing. Body composition changes required 3 to 6 months of continuous use in reported trials. Ipamorelin clinical timeline data for body composition are essentially absent; available human trials focused on GI motility endpoints.
Sources
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Thorner MO, Rochefort NB, Cowley MA, et al. Growth hormone-releasing hormone and growth hormone secretagogues: basic physiology and clinical implications. Endocrine Reviews. Multiple publications reviewed.
- FDA Center for Drug Evaluation and Research. Geref (sermorelin acetate) NDA approval documentation. Available at: FDA.gov.
- FDA. Bulk Drug Substances That May Not Be Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Federal Register. 2024.
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998;54(12):1316-1329.
- Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. Journal of Endocrinological Investigation. 2003;26(9):799-813.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
- U.S. National Library of Medicine. ClinicalTrials.gov. Helsinn ipamorelin (TZP-101) trials for postoperative ileus. NCT identifiers publicly searchable.
- Devesa J, Almenglo C, Devesa P. Multiple effects of growth hormone in the body: is it really the hormone for growth? Clinical Medicine Insights: Endocrinology and Diabetes. 2016;9:47-71.
- Svensson J, Lonn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology and Metabolism. 1998;83(2):362-369. (Mechanistic context for GHSR agonism in humans.)